View Item 

Show simple item record

The effect of mesalazine therapy on quality of life in patients with mildly and moderately active ulcerative colitis

dc.contributor.authorIrvine, E. J.en_US
dc.contributor.authorYeh, C.-H.en_US
dc.contributor.authorRamsey, D.en_US
dc.contributor.authorStirling, A. L.en_US
dc.contributor.authorHiggins, Peter D.R.en_US
dc.date.accessioned2010-06-01T21:57:53Z
dc.date.available2010-06-01T21:57:53Z
dc.date.issued2008-12en_US
dc.identifier.citationIRVINE, E. J.; YEH, C.-H.; RAMSEY, D.; STIRLING, A. L.; HIGGINS, P. D. R. (2008). "The effect of mesalazine therapy on quality of life in patients with mildly and moderately active ulcerative colitis." Alimentary Pharmacology & Therapeutics 28(11-12): 1278-1286. <http://hdl.handle.net/2027.42/74996>en_US
dc.identifier.issn0269-2813en_US
dc.identifier.issn1365-2036en_US
dc.identifier.urihttps://hdl.handle.net/2027.42/74996
dc.identifier.urihttp://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=18808446&dopt=citationen_US
dc.format.extent205868 bytes
dc.format.extent3109 bytes
dc.format.mimetypeapplication/pdf
dc.format.mimetypetext/plain
dc.publisherBlackwell Publishing Ltden_US
dc.rightsJournal compilation © 2008 Blackwell Publishing Ltden_US
dc.titleThe effect of mesalazine therapy on quality of life in patients with mildly and moderately active ulcerative colitisen_US
dc.typeArticleen_US
dc.subject.hlbsecondlevelOtolaryngologyen_US
dc.subject.hlbsecondlevelPharmacy and Pharmacologyen_US
dc.subject.hlbtoplevelHealth Sciencesen_US
dc.description.peerreviewedPeer Revieweden_US
dc.contributor.affiliationum§ Division of Gastroenterology and Hepatology, Department of Internal Medicine, University of Michigan Medical Center, Ann Arbor, MI, USAen_US
dc.contributor.affiliationother* Division of Gastroenterology, St. Michael’s Hospital, University of Toronto, Toronto, ON, Canadaen_US
dc.contributor.affiliationother† Procter & Gamble Pharmaceuticals, Inc., Mason, OH, USAen_US
dc.contributor.affiliationother† Medical Education Strategies, LLC, Tampa, FL, USAen_US
dc.identifier.pmid18808446en_US
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/74996/1/j.1365-2036.2008.03854.x.pdf
dc.identifier.doi10.1111/j.1365-2036.2008.03854.xen_US
dc.identifier.sourceAlimentary Pharmacology & Therapeuticsen_US
dc.identifier.citedreferenceCohen RD. The quality of life in patients with Crohn’s disease. Aliment Pharmacol Ther 2002; 16: 1603 – 9.en_US
dc.identifier.citedreferenceLove JR, Irvine EJ, Fedorak RN. Quality of life in inflammatory bowel disease. J Clin Gastroenterol 1992; 14: 15 – 9.en_US
dc.identifier.citedreferenceSainsbury A, Heatley RV. Review article: psychosocial factors in the quality of life of patients with inflammatory bowel disease. Aliment Pharmacol Ther 2005; 21: 499 – 508.en_US
dc.identifier.citedreferenceIrvine EJ. Quality of life in inflammatory bowel disease: biases and other factors affecting scores. Scand J Gastroenterol 1995; 208: 136 – 40.en_US
dc.identifier.citedreferenceIrvine EJ. Quality of life of patients with ulcerative colitis: past, present, and future. Inflamm Bowel Dis 2008; 14: 554 – 65.en_US
dc.identifier.citedreferenceIrvine EJ. Quality of life assessment in gastro-oesophageal reflux disease. Gut 2004; 53 ( Suppl. 4 ): 35 – 9.en_US
dc.identifier.citedreferenceDrossman DA, Patrick DL, Whitehead WE, et al. Further validation of the IBS-QOL: a disease-specific quality-of-life questionnaire. Am J Gastroenterol 2000; 95: 999 – 1007.en_US
dc.identifier.citedreferenceIrvine EJ, Feagan B, Rochon J, et al. Quality of life: a valid and reliable measure of therapeutic efficacy in the treatment of inflammatory bowel disease. Canadian Crohn’s Relapse Prevention Trial Study Group. Gastroenterology 1994; 106: 287 – 96.en_US
dc.identifier.citedreferenceHlavaty T, Persoons P, Vermeire S, et al. Evaluation of short-term responsiveness and cutoff values of inflammatory bowel disease questionnaire in Crohn’s disease. Inflamm Bowel Dis 2006; 12: 199 – 204.en_US
dc.identifier.citedreferenceHiggins PD, Schwartz M, Mapili J, Krokos I, Leung J, Zimmermann EM. Patient defined dichotomous end points for remission and clinical improvement in ulcerative colitis. Gut 2005; 54: 782 – 8.en_US
dc.identifier.citedreferenceFeagan BG, Reinisch W, Rutgeerts P, et al. The effects of infliximab therapy on health-related quality of life in ulcerative colitis patients. Am J Gastroenterol 2007; 102: 794 – 802.en_US
dc.identifier.citedreferenceHanauer SB, Sandborn WJ, Kornbluth A, et al. Delayed-release oral mesalamine at 4.8 g/day (800 mg tablet) for the treatment of moderately active ulcerative colitis: the ASCEND II trial. Am J Gastroenterol 2005; 100: 2478 – 85.en_US
dc.identifier.citedreferenceHanauer SB, Sandborn WJ, Dallaire C, et al. Delayed-release oral mesalamine 4.8 g/day (800 mg tablets) compared to 2.4 g/day (400 mg tablets) for the treatment of mildly to moderately active ulcerative colitis: the ASCEND I trial. Can J Gastroenterol 2007; 21: 827 – 34.en_US
dc.identifier.citedreferenceGuyatt G, Mitchell A, Irvine EJ, et al. A new measure of health status for clinical trials in inflammatory bowel disease. Gastroenterology 1989; 96: 804 – 10.en_US
dc.identifier.citedreferenceHan SW, McColl E, Steen N, Barton JR, Welfare MR. The inflammatory bowel disease questionnaire: a valid and reliable measure in ulcerative colitis patients in the North East of England. Scand J Gastroenterol 1998; 33: 961 – 6.en_US
dc.identifier.citedreferenceHanauer SB, Sandborn WJ, Kornbluth A, Hardi R, Regalli G, Yeh C. Delayed-release oral mesalamine 4.8 g/day (800 mg tablet) versus 2.4 g/day (400mg tablet) for treatment of moderately active ulcerative colitis: combined analysis of two randomized, double-blind, controlled trials. Gastroenterology 2005; 128: A74 – 5. Abstract 492.en_US
dc.identifier.citedreferenceRobinson M, Hanauer S, Hoop R, Zbrozek A, Wilkinson C. Mesalamine capsules enhance the quality of life for patients with ulcerative colitis. Aliment Pharmacol Ther 1994; 8: 27 – 34.en_US
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
j.1365-2036.2008.03854.x.pdf
Size:
201.0KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.